Azenta, Inc.

NasdaqGS:AZTA Rapport sur les actions

Capitalisation boursière : US$774.4m

Azenta Croissance future

Future contrôle des critères 3/6

Azenta devrait augmenter ses bénéfices et son chiffre d'affaires de 95.1% et de 5% par an respectivement. Le BPA devrait croître de de 90.1% par an. Le rendement des capitaux propres devrait être 0.9% dans 3 ans.

Informations clés

95.1%

Taux de croissance des bénéfices

90.15%

Taux de croissance du BPA

Life Sciences croissance des bénéfices17.5%
Taux de croissance des recettes5.0%
Rendement futur des capitaux propres0.85%
Couverture par les analystes

Good

Dernière mise à jour08 May 2026

Mises à jour récentes de la croissance future

Recent updates

Mise à jour du récit • May 01

AZTA: 2026 Guidance And Space Research Partnership Will Support Sentiment Recovery

Azenta's updated analyst price target has moved modestly lower by about $0.77, as analysts factor in refreshed assumptions for fair value, discount rate, revenue growth, profit margin, and future P/E following a series of recent target cuts from major firms. Analyst Commentary Recent Street research has focused on recalibrating Azenta's fair value, with several firms trimming their price targets by between $5 and $10 as they reassess assumptions for growth, profitability, and appropriate P/E levels.
Mise à jour du récit • Apr 15

AZTA: 2026 Guidance And Space Research Will Support Sentiment Recovery

Azenta's analyst price target has been trimmed by about $2.50 as analysts factor in updated assumptions for fair value, discount rate, revenue growth, profit margin, and future P/E following a series of recent target cuts from major firms. Analyst Commentary Recent Street research on Azenta points to a more cautious tone on valuation, with multiple price target trims clustering over a relatively short period.
Mise à jour du récit • Apr 01

AZTA: 2026 Guidance And Space Research Tests Will Support Sentiment Recovery

Azenta's analyst price targets have been reduced by $5 to $9 in recent updates, as analysts factor in revised expectations for the diagnostic tools group and place greater emphasis on 2026 guidance and the clarity of the company's multi year growth framework. Analyst Commentary Recent research updates on Azenta show a mix of optimism around the long term framework and caution around the nearer term setup, with price targets adjusted both higher and lower as estimates and expectations are refreshed.
Seeking Alpha • Mar 24

Azenta: Life Science Player Fails To Come To Life

Summary Azenta, Inc. trades near $20, with operating assets valued at just 0.5x sales and a robust net cash position around $600 million. Recent AZTA developments include the UK Biocentre acquisition and B Medical Systems divestiture, with the latter removing a key earnings drag. Despite a soft Q1 and margin pressure, Azenta maintains full-year guidance, supported by remediation efforts and interest income. The AZTA risk/reward is compelling at current levels, given low expectations, significant liquidity, and underappreciated asset value, making me a buyer despite above-average risks. Read the full article on Seeking Alpha
Mise à jour du récit • Mar 18

AZTA: 2026 Guidance And Space Research Partnership Will Support Sentiment Recovery

Azenta's analyst price targets have edged lower by a mid single digit dollar amount to around $39, as analysts factor in updated discount rate and growth assumptions, while still highlighting the importance of 2026 guidance and multi year frameworks for potential upside. Analyst Commentary Bullish Takeaways Bullish analysts point to the move to a US$39 price target as a reflection of clearer multi year planning, which supports their view that the company has several paths to grow into that valuation over time.
Mise à jour du récit • Mar 03

AZTA: 2026 Framework And Buybacks Will Underpin Sentiment Recovery

Narrative Update: Azenta Azenta's latest analyst price targets have shifted slightly lower in recent research updates, with firms trimming their views by $5 and $9 after a prior increase to $39, as analysts factor in group wide adjustments in diagnostic tools and place more weight on visibility into the company's multi year framework and 2026 guidance. Analyst Commentary Recent research updates on Azenta reflect a mix of optimism about the long term setup and caution around execution and visibility, especially as analysts refresh their views on the broader diagnostic tools group and Azenta's multi year framework.
Nouveau récit • Feb 25

Automation And Biorepositories Will Steadily Support A Fairly Valued Long Term Outlook

Catalysts About Azenta Azenta provides life sciences customers with sample management, biorepositories and multiomics services such as next-generation sequencing and gene synthesis. What are the underlying business or industry changes driving this perspective?
Mise à jour du récit • Feb 17

AZTA: 2026 Margin Framework And Buybacks Will Support Future Upside

Analysts have trimmed their average price target on Azenta from about $43.50 to roughly $38.67, reflecting recent target cuts of $5 and $9, along with updated views on revenue growth, margins and a lower future P/E assumption. Analyst Commentary Recent research shows a mixed but detailed set of views around Azenta, with some focusing on long term growth potential and others dialing back expectations on valuation and near term execution.
Nouveau récit • Feb 08

Multiomics Outsourcing And Automation Will Drive A Powerful Long Term Earnings Shift

Catalysts About Azenta Azenta provides life sciences customers with sample management, multiomics services and automation solutions across biorepositories, sequencing and gene synthesis. What are the underlying business or industry changes driving this perspective?
Mise à jour du récit • Feb 03

AZTA: 2026 Margin Path And Buybacks Will Support Upside Potential

Analysts have nudged up their Azenta targets, with one moving to US$39 and another to US$45. This reflects interest in the company’s multi year growth framework and expectations for mid single digit organic revenue trends, with a path to margins above 20%.
Mise à jour du récit • Jan 20

AZTA: Biopharma Exposure And 2026 Margin Path Support Balanced Risk Reward

Analysts have lifted their price target on Azenta to about US$43.50 from roughly US$40.17, citing slightly lower revenue growth expectations, firmer profit margin assumptions and a modestly lower future P/E outlook. The revised target is supported by recent research that notes improving sentiment, mid single digit organic revenue ambitions and a path to higher margins into 2026.
Mise à jour du récit • Jan 05

AZTA: Biopharma Exposure Will Support Margin Expansion And 2026 Re Rating Potential

Analysts have nudged their fair value estimate for Azenta slightly higher to about $40, reflecting updated price targets in the mid to high $30s and low $40s, and their view that organic revenue growth and margin expansion potential into 2026 support a more constructive outlook on the shares. Analyst Commentary Recent research updates highlight a more constructive tone on Azenta, with several firms lifting price targets and turning more positive after the latest fiscal Q4 report and ahead of the upcoming investor day.
Mise à jour du récit • Dec 14

AZTA: Biopharma Exposure Will Support Mid-Single-Digit Growth And Margin Expansion

Azenta's analyst price target has been raised by $10 to $45, as analysts point to mid single digit plus organic revenue growth prospects and a credible path to margins above 20% that is supported by healthy biopharma exposure and multiple growth drivers into 2026. Analyst Commentary Bullish analysts highlight that the latest results, while largely in line with expectations, reinforce confidence in Azenta's ability to sustain mid single digit plus organic revenue growth while steadily expanding margins above 20% over the medium term.
Mise à jour du récit • Nov 29

AZTA: Mid-Single-Digit Organic Revenue Acceleration Will Broaden Profit Margins Into 2026

Azenta's analyst price target has increased from $35.17 to $39.83. Analysts cite in-line financial results and ongoing optimism around revenue growth and expanding profit margins, supported by sector exposure and long-term innovation opportunities.
Article d’analyse • Nov 28

Azenta's (NASDAQ:AZTA) Earnings Offer More Than Meets The Eye

Investors signalled that they were pleased with Azenta, Inc.'s ( NASDAQ:AZTA ) most recent earnings report. Looking...
Mise à jour du récit • Nov 14

AZTA: Growth Drivers From Biopharma Exposure And Acquisitions Will Unlock Opportunity

Analysts have raised their price target for Azenta from $30 to $38, citing expectations for increased growth opportunities and a positive outlook. This outlook is based on innovation, robust biopharma exposure, and prospective acquisitions.
Mise à jour du récit • Oct 30

AZTA: Biopharma Demand and Acquisition Focus Will Drive Shares Higher Through 2026

Azenta's analyst price target has been raised from $33 to approximately $35.17 per share. Analysts cite increased confidence in the company's growth drivers and mid-term opportunities, particularly within the biopharma sector.
Article d’analyse • Sep 12

Is There Now An Opportunity In Azenta, Inc. (NASDAQ:AZTA)?

While Azenta, Inc. ( NASDAQ:AZTA ) might not have the largest market cap around , it saw a decent share price growth of...
Article d’analyse • Aug 07

Azenta, Inc. (NASDAQ:AZTA) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates

NasdaqGS:AZTA 1 Year Share Price vs Fair Value Explore Azenta's Fair Values from the Community and select yours It's...
Article d’analyse • Jul 24

Calculating The Fair Value Of Azenta, Inc. (NASDAQ:AZTA)

Key Insights Azenta's estimated fair value is US$38.26 based on 2 Stage Free Cash Flow to Equity Current share price of...
User avatar
Nouveau récit • May 28

Pharma And Biotech Outsourcing Will Shape Future Market Dynamics

Strong industry trends and Azenta's infrastructure investments are driving above-market growth, recurring revenues, and operating leverage in sample management and biobanking.
Seeking Alpha • Apr 17

Azenta: Life Science Business Failing To Come To Life

Summary Azenta, formerly Brooks Automation, has struggled to show organic growth and profitability, leading to a significant drop in its stock price. Despite a strong balance sheet and reduced valuation, the company needs to deliver real margin growth and profitability to attract investors. The company has faced challenges, including a decline in organic sales and the departure of its CEO, but continues to make strategic moves like selling B Medical Systems. Given the compressed sales multiples and strong cash position, a speculative position might be warranted, but management must prove its ability to improve earnings. Read the full article on Seeking Alpha
Article d’analyse • Apr 05

Azenta, Inc.'s (NASDAQ:AZTA) 29% Share Price Plunge Could Signal Some Risk

Unfortunately for some shareholders, the Azenta, Inc. ( NASDAQ:AZTA ) share price has dived 29% in the last thirty...
Article d’analyse • Mar 28

Are Investors Undervaluing Azenta, Inc. (NASDAQ:AZTA) By 50%?

Key Insights Using the 2 Stage Free Cash Flow to Equity, Azenta fair value estimate is US$70.94 Current share price of...
Seeking Alpha • Jan 27

Azenta: Taking A Pass

Summary Azenta, Inc. shares have surged over 30% since Nov 2024 due to S&P 600 inclusion and an analyst upgrade, despite somewhat tepid growth prospects. The company is restructuring to save $30-$40 million by FY26, divesting a business segment, and has a strong balance sheet. An analysis on Azenta, Inc. follows in the paragraphs below. Read the full article on Seeking Alpha
Article d’analyse • Jan 10

At US$51.81, Is Azenta, Inc. (NASDAQ:AZTA) Worth Looking At Closely?

Azenta, Inc. ( NASDAQ:AZTA ), is not the largest company out there, but it received a lot of attention from a...
Article d’analyse • Dec 20

A Look At The Intrinsic Value Of Azenta, Inc. (NASDAQ:AZTA)

Key Insights The projected fair value for Azenta is US$56.65 based on 2 Stage Free Cash Flow to Equity With US$49.50...
Article d’analyse • Nov 17

Analysts Have Just Cut Their Azenta, Inc. (NASDAQ:AZTA) Revenue Estimates By 14%

The analysts covering Azenta, Inc. ( NASDAQ:AZTA ) delivered a dose of negativity to shareholders today, by making a...
Article d’analyse • Nov 14

Shareholders Should Be Pleased With Azenta, Inc.'s (NASDAQ:AZTA) Price

It's not a stretch to say that Azenta, Inc.'s ( NASDAQ:AZTA ) price-to-sales (or "P/S") ratio of 3.1x right now seems...
Seeking Alpha • Sep 11

Azenta: Life Science Play Is Not Coming To Life

Summary Azenta, Inc., formerly Brooks Automation, has struggled after the sale of its semiconductor business, as the remaining life sciences business has failed to turn a profit. Following aggressive share buybacks, Azenta's valuation remains demanding, with high earnings multiples and significant discrepancies between GAAP and non-GAAP earnings. New CEO John Marotta brings industry experience, but immediate results are unlikely, as the company needs to improve its margin profile and organic growth. I remain cautious on Azenta, monitoring its progress under new leadership, despite the seemingly low sales multiple and strong revenue base. Read the full article on Seeking Alpha
Article d’analyse • Jul 19

Azenta, Inc.'s (NASDAQ:AZTA) Shares May Have Run Too Fast Too Soon

When close to half the companies in the Life Sciences industry in the United States have price-to-sales ratios (or...

Prévisions de croissance des bénéfices et des revenus

NasdaqGS:AZTA - Estimations futures des analystes et données financières antérieures (USD Millions )
DateRecettesLes revenusFlux de trésorerie disponibleCash from OpMoy. Nombre d'analystes
9/30/20286752150904
9/30/20276301741806
9/30/2026600-15940736
3/31/2026596-1113062N/A
12/31/2025595263163N/A
9/30/2025594243872N/A
6/30/2025586-275288N/A
3/31/2025586-283972N/A
12/31/2024579-243266N/A
9/30/2024573-241250N/A
6/30/2024595-212462N/A
3/31/2024616-233169N/A
12/31/2023628-91048N/A
9/30/2023551-8-346N/A
6/30/2023630-21-56-13N/A
3/31/2023597-26-500-449N/A
12/31/2022594-25-581-509N/A
9/30/2022555-11-543-466N/A
6/30/2022555-28-530-449N/A
3/31/2022551-23-5916N/A
12/31/2021535-2966122N/A
9/30/2021514-2997150N/A
6/30/2021114-69130175N/A
3/31/2021205-53112156N/A
12/31/2020296-371056N/A
9/30/2020389-26-238N/A
6/30/202085041-1919N/A
3/31/202083428-729N/A
12/31/201981216N/A110N/A
9/30/2019334-61N/A91N/A
6/30/20197413N/A89N/A
3/31/20197107N/A73N/A
12/31/201866872N/A77N/A
9/30/201863268N/A74N/A
6/30/201848835N/A78N/A
3/31/201849847N/A76N/A
12/31/2017510-2N/A81N/A
9/30/201752711N/A96N/A
6/30/201766956N/A85N/A
3/31/201763447N/A82N/A
12/31/2016600-51N/A71N/A
9/30/2016434-85N/A40N/A
6/30/2016549-73N/A38N/A
3/31/2016546-74N/A39N/A
12/31/201555012N/A28N/A
9/30/201555314N/A44N/A
6/30/20155298N/A35N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: AZTA devrait devenir rentable au cours des 3 prochaines années, ce qui est considéré comme une croissance plus rapide que le taux d'épargne ( 3.5% ).

Bénéfices vs marché: AZTA devrait devenir rentable au cours des 3 prochaines années, ce qui est considéré comme une croissance supérieure à la moyenne du marché.

Croissance élevée des bénéfices: AZTA devrait devenir rentable dans les 3 prochaines années.

Chiffre d'affaires vs marché: Le chiffre d'affaires de AZTA ( 5% par an) devrait croître plus lentement que le marché de US ( 11.7% par an).

Croissance élevée des revenus: Le chiffre d'affaires de AZTA ( 5% par an) devrait croître plus lentement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Le retour sur capitaux propres de AZTA devrait être faible dans 3 ans ( 0.9 %).

Découvrir les entreprises en croissance

7D

1Y

7D

1Y

7D

1Y

Analyse de l'entreprise et données financières

DonnéesDernière mise à jour (heure UTC)
Analyse de l'entreprise2026/05/15 12:34
Cours de l'action en fin de journée2026/05/15 00:00
Les revenus2026/03/31
Revenus annuels2025/09/30

Sources de données

Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.

PaquetDonnéesCadre temporelExemple de source américaine *
Finances de l'entreprise10 ans
  • Compte de résultat
  • Tableau des flux de trésorerie
  • Bilan
Estimations consensuelles des analystes+3 ans
  • Prévisions financières
  • Objectifs de prix des analystes
Prix du marché30 ans
  • Cours des actions
  • Dividendes, scissions et actions
Propriété10 ans
  • Actionnaires principaux
  • Délits d'initiés
Gestion10 ans
  • L'équipe dirigeante
  • Conseil d'administration
Principaux développements10 ans
  • Annonces de l'entreprise

* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.

Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.

Modèle d'analyse et flocon de neige

Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.

Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.

Indicateurs de l'industrie et du secteur

Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.

Sources des analystes

Azenta, Inc. est couverte par 15 analystes. 6 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.

AnalysteInstitution
Christopher MuseBarclays
Brett HodessBofA Global Research
Paul KnightBrean Capital Historical (Janney Montgomery)